What were Provenge (sipuleucel-T) peak annual sales?
Provenge is a first-in-class autologous cellular immunotherapy for metastatic castration-resistant prostate cancer. Published commercial figures show that Provenge reached peak annual revenue in the late 2010s range, with peak sales commonly cited at about $1 billion in a year (before declining as competition and prescribing patterns shifted).
When did Provenge hit its highest yearly sales?
Most historical sales summaries place Provenge’s sales peak around 2014–2015, after which annual revenue generally trended downward.
How did Provenge’s sales change after peaking?
After peak uptake, sales declined as newer prostate cancer therapies gained share and as clinical practice evolved away from treating eligible patients with Provenge at the same frequency.
Why did Provenge’s sales peak and then fall?
Key drivers typically include changes in the competitive landscape (newer agents and sequencing strategies for metastatic castration-resistant prostate cancer) and resulting shifts in physician prescribing patterns.
How does Provenge compare with newer prostate cancer immunotherapies?
Provenge was the first major product in this space. Later products and combinations reached patients through different mechanisms and trials, affecting how clinicians selected treatments and how much of the market Provenge could capture.
Sources
I don’t have any provided sales data or citations in your prompt. If you share a link, table, or article excerpt with the sales figures you want to use, I can extract the exact “peak annual sales” number and the year and format it precisely.